Back to results
US 2025/0025514 A1Published application
Treatment of systemic inflammatory responses
AssigneeNoveome Biotherapeutics, Inc.
InventorsLarry R. Brown, Howard C. Wessel
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNoveome Biotherapeutics, Inc.
InventorsLarry R. Brown, Howard C. Wessel
Estimating the term…
The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
A method of treating vascular permeability caused by an infectious disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of amnion-derived cellular cytokine solution (ACCS), wherein the ACCS comprises physiological concentrations of vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiogenin, platelet-derived growth factor (PDGF), tissue inhibitor of metalloproteinase 1 (TIMP 1), and tissue inhibitor of metalloproteinase 2 (TIMP 2), and wherein the physiological concentrations range is ˜5-16 ng/ml for VEGF, ˜2.5-2.7 ng/ml for TGFβ2, ˜3.5-4.5 ng/ml for angiogenin, ˜100-165 pg/mL for PDGF, ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2.
A method of treating vascular permeability caused by an infectious disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of amnion-derived cellular cytokine solution (ACCS), wherein the ACCS comprises physiological concentrations of vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiogenin, platelet-derived growth factor (PDGF), tissue inhibitor of metalloproteinase 1 (TIMP 1), and tissue inhibitor of metalloproteinase 2 (TIMP 2), wherein the physiological concentrations range is ˜5-16 ng/mL for VEGF, ˜2.5-2.7 ng/ml for TGFβ2, ˜3.5-4.5 ng/mL for angiogenin, ˜100-165 pg/mL for PDGF, ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and wherein the ACCS modulates vascular permeability in endothelial cells.
A method of treating vascular permeability caused by an infectious disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of amnion-derived cellular cytokine solution (ACCS), wherein the ACCS comprises physiological concentrations of vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiogenin, platelet-derived growth factor (PDGF), tissue inhibitor of metalloproteinase 1 (TIMP 1), and tissue inhibitor of metalloproteinase 2 (TIMP 2), wherein the physiological concentrations range is ˜5-16 ng/mL for VEGF, ˜2.5-2.7 ng/mL for TGFß2, ˜3.5-4.5 ng/ml for angiogenin, ˜100-165 pg/mL for PDGF, ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and wherein the infectious disease is characterized by at least one of hypotension, tachycardia, dyspnea, fever, ischemia or insufficient tissue perfusion, uncontrollable hemorrhage, severe metabolism dysregulation, and multisystem organ failure.
Dependencies are inferred from the claim text.